Zylox-Tonbridge IPO: Valuation Insights
Our base-case DCF valuation is HK$48.56 per share, which is an 18% upside to the mid-point of the IPO price range of HK$39.80-42.70 per share....
366 Views
Zylox-Tonbridge IPO: Comprehensive Coverage, Proven Marketing and Core Products Show Good Potential
Zylox's revenues in 2020 includes only 2-3 months of revenues from the two core products, however, the two products together accounted for about...
289 Views
Zylox-Tonbridge IPO: Living On
Zylox-Tonbridge has launched an HKEx IPO to raise net proceeds of $300 million at the mid-point of the IPO price range. Overall, we believe that...
420 Views
Zylox-Tonbridge (归创通桥) IPO: Clear Upside Thanks to Comprehensive Coverage
With its comprehensive product coverage in the neuro- and peripheral interventional device segment, we think there's a clear valuation upside for...
321 Views
ECM Weekly (20th June 2021) - Didi, Nayuki, Soulgate, Hutchmed, Full Truck, CTOS, Cloud Village
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
409 Views